BD’s Onclarity HPV Assay: What it means for the future of cervical cancer detection

Explore the efficacy of Pivya (pivmecillinam; Utility Therapeutics) tablets in managing uncomplicated urinary tract infections in female adults, supported by controlled clinical trials and safety considerations.

In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.

As a potential alternative to antibiotic treatments, this investigational immunization offered protection for several years.

In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.

The FDA's Fast Track Designation for nipocalimab marks a significant step in addressing fetal neonatal alloimmune thrombocytopenia risk in pregnant patients, potentially revolutionizing treatment for this severe condition with unmet medical needs.

GlaxoSmithKline's phase 3 trial demonstrated promising overall and progression-free survival outcomes in patients with primary advanced or recurrent endometrial cancer, paving the way for potential FDA approval.